117 results about "TLR7" patented technology

The invention discloses a viral ARDS prognosis evaluation system based on protein joint detection, and the system comprises a sample processing module which is used for carrying out serum standardization pretreatment; the protein detection module is used for performing iBAQ quantification of IL6ST / FOXO3 / TLR7 based on DIA mass spectrometry, defining a targeted therapy threshold value and realizing targeted quantification of the core protein; and the intelligent analysis module is used for realizing cross-age risk layering based on a multivariable logic regression model. B cell function states are reflected by combining serum IL6ST / FOXO3 / TLR7 protein expression levels, a multivariable logistic regression model is constructed, and unified risk stratification of patients of all ages from children to the elderly is achieved; by locking an IL6ST / FOXO3 / TLR7 pathway, a targeted therapy threshold is defined to directly guide targeted therapy, and immune intervention is facilitated.

The invention belongs to the technical field of molecular biology, and particularly discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The nano antibody can be specifically combined with a B cell antigen epitope of bovine TLR7 protein, and the B cell antigen epitope is selected from SEQ ID NO: 1 and / or SEQ ID NO: 2. The invention discloses a specific nano antibody targeting bovine TLR7 protein as well as a screening method and application of the specific nano antibody. The specific nano antibody targeting bovine TLR7 protein is high in stability and specificity and has super-strong affinity.

The invention belongs to the technical field of biological medicines, and particularly relates to an MAF vaccine as well as a preparation method and application thereof. In order to develop a nasal spray type vaccine capable of effectively preventing and treating fibrotic interstitial lung diseases and avoiding risk increase caused by local inflammatory reaction, the invention adopts two modes of taking a synthesized MAF protein as a model antigen, encapsulating the MAF protein by using a TLR7 adjuvant to form a peptide fragment vaccine or constructing an MAF adenovirus vaccine based on an adenovirus vector. Two vaccines based on the MAF target spot are successfully constructed. Animal experiment results prove that the two vaccines based on the MAF target spot have treatment and prevention effects on bleomycin-induced mouse pulmonary fibrosis models during nasal dripping immunization, and also have good safety in vivo. A good candidate vaccine is provided for future fibrotic disease prevention and treatment vaccine transformation research and clinical experiment development.

The invention discloses an SNP molecular marker combination related to disease resistance of ricefield eels and application of the SNP molecular marker combination, and relates to the technical field of molecular biology. The SNP molecular marker combination comprises the following molecular markers (1)-(3): (1) a molecular marker with a nucleotide sequence as shown in SEQ ID NO.7; (2) a molecular marker with a nucleotide sequence as shown in SEQ ID NO.8; and (3) a molecular marker with a nucleotide sequence as shown in SEQ ID NO.9. According to the invention, an SNP locus in a TLR7 gene in a monopterus albus group is screened through sequence alignment, and genotyping is carried out on the SNP locus; and comparing the differences of the disease resistance of the genotypes, and screening to obtain the genotype with the strongest disease resistance, thereby providing an effective molecular marker for detecting the disease resistance of the ricefield eel. The molecular marker combination provided by the invention is associated with the disease resistance of the monopterus albus, and provides effective technical support for breeding of disease-resistant monopterus albus varieties.

Provided in the present invention are an anti-TLR7 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition thereof. The antibody or the antigen-binding fragment thereof can specifically bind to a human or simian TLR7 antigen and does not bind to murine TLR7, exhibits significant TLR7 antigen-binding activity, and can effectively inhibit various inflammatory cytokines produced upon TLR7 activation. The anti-TLR7 antibody or the antigen-binding fragment thereof can be used, either as a monotherapy or in combination with other drugs, for treating and / or preventing diseases pathologically associated with the TLR7 target, including immune inflammation-related diseases, allergic diseases, infectious diseases, cancers, etc.

The invention provides an anti-TLR7 antibody or an antigen binding fragment and a pharmaceutical composition thereof, the antibody or the antigen binding fragment thereof can be specifically bound with a human or monkey TLR7 antigen and is not bound with mouse TLR7, has remarkable TLR7 antigen binding activity, and can effectively inhibit various inflammatory cytokines generated by TLR7 activation. The anti-TLR7 antibody or the antigen binding fragment thereof can be used as a single agent or a drug combination and can be used for treating and / or preventing diseases related to TLR7 target pathology, including immune inflammation related diseases, allergic diseases, infectious diseases or cancers and the like.

The present application relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, as a Toll-like Receptor 7 (TLR7) agonist, for use in the treatment of lung cancer, a pharmaceutical combination of a TLR7 agonist and a tyrosine kinase inhibitor for use in the treatment of lung cancer, and the use of a compound of Formula I or a pharmaceutically acceptable salt thereof in the pharmaceutical combination in the treatment of lung cancer.

The invention provides a TOLL-like receptor 7 (TLR7) specific antagonist as well as a preparation method and application of the TOLL-like receptor 7 (TLR7) specific antagonist. The TLR7 antagonist has a structure as shown in a formula (I) or a formula (II), has outstanding TLR7 antagonistic activity and selectivity, and is expected to be applied to prevention and treatment of related diseases.

The present disclosure provides methods of treating or inhibiting cancer, reducing its severity, reducing its risk, or inhibiting its metastasis in an individual with a radiation-activated N-oxide TLR7 / 8 agonist.

Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

Lipidized oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. These compounds may have therapeutic applications in the treatment of cancer, infectious diseases, allergies, or autoimmune disorders (SEE FORMULA).

The TLR7 inhibitory effect of CB-7 in normal mice is weak. The present invention provides a novel compound having a TLR7 inhibitory effect higher than that of CB-7, a pharmacologically acceptable salt thereof, or a prodrug thereof. In addition, the present invention also provides a prophylactic or therapeutic agent for a disease accompanied by TLR7 activation, which contains the above TLR7 activation inhibitor.

Lipidated oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.

Stable aqueous formulations of adjuvant comprising a TLR7 / 8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.

The present invention relates to a conjugate of cholesterol and a TLR7 agonist that is useful as a drug, a pharmaceutically acceptable salt thereof, and a drug composition or cancer treatment vaccine containing the same as an active ingredient.

The invention relates to the technical field of medicine, in particular to a nitrile compound and application of the nitrile compound in disease treatment medicine, and the chemical structural formula of the nitrile compound is shown in the formula I in the specification. The invention also provides a pharmaceutical composition containing the compound. The invention finds that the compound with the nitrile structure shows an excellent TLR7 agonist effect and can be used for treating diseases related to TLR7.

The present invention provides a method for activating an N-oxide TLR7 / 8 agonist using radiation and a method for treating or inhibiting cancer, reducing its severity, lowering its risk, or inhibiting metastasis.

This invention discloses a photoactivated nanoparticle-based drug delivery material for immunoadjuvants, its preparation method, and its applications. The drug delivery material is constructed from photosensitizer monomers, crosslinking monomers, and immunoadjuvant prodrug monomers within a confined space of a nanoemulsion via a copper-free click polymerization reaction to form crosslinked polymer nanoparticles. The nanoparticle size is controllable, and the composition is precisely defined. Under physiological conditions, the drug delivery material exhibits good colloidal stability and high drug loading. Upon near-infrared light irradiation, the generated ROS can cleave the thioketone bonds, causing the nanoparticles to depolymerize and achieving photo-triggered, controllable release of the immunoadjuvant. Under photodynamic action, this drug delivery material efficiently generates reactive oxygen species to induce immunogenic cell death in tumor cells. Simultaneously, the released immunoadjuvant activates the TLR7 / 8 pathway, promotes dendritic cell maturation, and enhances the systemic anti-tumor immune response, thereby inhibiting the growth of tumors in situ and at distant sites, and reducing the risk of metastasis and recurrence.

An imidazo [2,1-f] [1,2,4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof which are used as a TLR7 agonist in the treatment of cancer are provided. Pharmaceutical compositions comprising the imidazo [2,1-f] [1,2,4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof are also provided.

The present invention relates to compounds of formula (I) and pharmaceutically acceptable compositions thereof useful as toll-like receptor 7 / 8 (TLR7 / 8) antagonists.SOLUTION: In Formula (I), ring A is aryl or heteroaryl; ring B is aryl or heteroaryl; and X is C (R4) 2, O, NR4, S, S (R4), or S (R4) 2.SELECTED DRAWING: None

The present invention relates to immune stimulating micelle compositions, and their use in treatment of diseases and disorders, such as cancer. In particular, the present invention relates to micelle compositions comprising a TLR7 agonist, such as 1V270.

The invention discloses an application of 8-methyl quercetin in preparation of a TLR7 (toll-like receptor 7) immunomodulator. According to the invention, it is found that 8-methyl quercetin can be used as a ligand of TLR7, and the 8-methyl quercetin has strong binding and interaction with swine TLR7 protein. Therefore, the 8-methyl quercetin can be used as an immunomodulator or a lead compound acting on the TLR7. As the TLR7 protein is conservative in evolution, the application of the 8-methyl quercetin is not limited to pigs, and the 8-methyl quercetin can also be applied to other species.

The present invention provides a chimeric antigen receptor, a nucleic acid molecule, CAR-Ms, and applications thereof, and belongs to the field of biomedical engineering and peptides. The chimeric antigen receptor provided by the present invention comprises a CD8 α leader signal peptide, a single-chain variable fragment, a CD8 α hinge, a CD8 transmembrane domain, and an intracellular co-stimulatory signal transduction domain. The single-chain variable fragment can target any known antigen; the intracellular co-stimulatory signal transduction domain is any one or a combination of TLR2, TLR4, TLR7, Mincle, Dectin-1, NOD2, CD40, 4-1BB, OX40, and CD3ζ. The present invention also provides a macrophage-targeted nanogel for RNA delivery. Macrophages transfected with the nanogel system express chimeric antigen receptors, which can achieve specific targeting and phagocytosis of known antigen-positive (e.g., MUC1) tumor cells.

The invention relates to a compound as shown in a formula (I) and an isotope form, a stereoisomer, a tautomer, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, hydrate, prodrug and polymorphic substance thereof, the compound as shown in the formula (I) can be used as a TLR inhibitor, effectively inhibits the expression level of TLR, especially double inhibition on TLR7 / 8, and can be used for preparing a TLR inhibitor. The compound has a good application prospect in the aspect of preparing medicines for treating TLR activity mediated diseases.

The present disclosure describes methods, compositions, and kits related to the combination of a TLR7 modulating compound and an HIV vaccine. The combination can be used in a method of treating or preventing an HIV infection in a human.